IFNB1 and myeloid sarcoma: On the other side, Hosback et al. (2007) observed an increase of serum IGF-1 levels in MS patients on IFN-β therapy compared to untreated MS patients, but high percentages of our patients were not receiving any specific immune modulation treatment which should be considered.